JP2011500780A - 新規結晶形 - Google Patents

新規結晶形 Download PDF

Info

Publication number
JP2011500780A
JP2011500780A JP2010530564A JP2010530564A JP2011500780A JP 2011500780 A JP2011500780 A JP 2011500780A JP 2010530564 A JP2010530564 A JP 2010530564A JP 2010530564 A JP2010530564 A JP 2010530564A JP 2011500780 A JP2011500780 A JP 2011500780A
Authority
JP
Japan
Prior art keywords
bosentan
crystalline
crystal form
solid
until
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010530564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500780A5 (enExample
Inventor
アブヘイ・ガイトンデ
ビンドゥ・マノジュクマール
サンディープ・メクデ
プラカシュ・バンソーデ
ダッタトラヤ・シンデ
スナンダ・パドタール
Original Assignee
ジェネリクス・（ユーケー）・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネリクス・（ユーケー）・リミテッド filed Critical ジェネリクス・（ユーケー）・リミテッド
Publication of JP2011500780A publication Critical patent/JP2011500780A/ja
Publication of JP2011500780A5 publication Critical patent/JP2011500780A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010530564A 2007-10-24 2008-10-24 新規結晶形 Pending JP2011500780A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2108MU2007 2007-10-24
PCT/GB2008/050986 WO2009053748A2 (en) 2007-10-24 2008-10-24 Novel crystalline forms

Publications (2)

Publication Number Publication Date
JP2011500780A true JP2011500780A (ja) 2011-01-06
JP2011500780A5 JP2011500780A5 (enExample) 2011-12-08

Family

ID=40262729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530564A Pending JP2011500780A (ja) 2007-10-24 2008-10-24 新規結晶形

Country Status (8)

Country Link
US (1) US8530488B2 (enExample)
EP (1) EP2222649A2 (enExample)
JP (1) JP2011500780A (enExample)
CN (1) CN101939303B (enExample)
AU (1) AU2008315757A1 (enExample)
CA (1) CA2703230A1 (enExample)
NZ (2) NZ585438A (enExample)
WO (1) WO2009053748A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508767A (ja) * 2008-01-01 2011-03-17 シプラ・リミテッド ボセンタン、その多形形態及びその塩の合成方法
JP2020143080A (ja) * 2012-04-04 2020-09-10 アルカヘスト インコーポレイテッド Ｃｃｒ３アンタゴニストを含む医薬製剤

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008135795A2 (en) * 2007-05-08 2008-11-13 Generics [Uk] Limited Polymorphic forms of bosentan
WO2009004374A1 (en) * 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
US20110263623A1 (en) 2008-08-12 2011-10-27 Cadila Healthcare Limited Process for preparation of bosentan
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
PL402305A1 (pl) * 2012-12-30 2014-07-07 Instytut Farmaceutyczny Sposób wytwarzania bozentanu w postaci monohydratu o czystości farmaceutycznej

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6185370A (ja) * 1984-09-24 1986-04-30 ルセル‐ユクラフ ４ｈ‐１，２，４‐トリアゾール誘導体の新製造法、得られる新トリアゾール、それらの薬剤としての使用及びそれらを含む製薬組成物
JPH05222003A (ja) * 1991-06-13 1993-08-31 F Hoffmann La Roche Ag スルホンアミド類および薬物としてのそれらの使用
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
JP2003520857A (ja) * 2000-01-25 2003-07-08 エフ．ホフマン−ラ ロシュ アーゲー スルホンアミドの製造

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276004A (en) * 1987-03-20 1994-01-04 Dai Nippon Insatsu Kabushiki Kaisha Process for heat transfer recording
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
SI1535613T1 (sl) 1999-11-17 2010-12-31 Teva Pharma Postopek za pripravo polimorfne oblike atorvastatin kalcija
HUP0204069A3 (en) 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
AU2003209669A1 (en) 2003-02-25 2004-09-17 Hetero Drugs Limited Amorphous form of losartan potassium
US7872019B2 (en) 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
WO2004087660A1 (en) 2003-04-02 2004-10-14 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
BRPI0809171A2 (pt) * 2007-04-02 2014-09-16 Auspex Pharmaceuticals Inc "composto, composição farmacêutica, método para tratamento,prevençõ ou melhora de um ou mais , sintomas de uma desordem mediada pela endotelina em um sujeito, método de inibição de ligação d euma endotelina a um receptor eta ou etb e método para modular a atividade mediada pelo receptor de endotelina"
WO2008135795A2 (en) 2007-05-08 2008-11-13 Generics [Uk] Limited Polymorphic forms of bosentan
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
EP2205591A1 (en) 2007-10-11 2010-07-14 Actavis Group PTC EHF Novel polymorphs of bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
ATE530531T1 (de) 2007-12-18 2011-11-15 Dipharma Francis Srl Verfahren zur herstellung von bosentan
WO2009095933A2 (en) 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
WO2009112954A2 (en) 2008-03-13 2009-09-17 Actavis Group Ptc Ehf Processes for the preparation of bosentan and related compounds using novel intermediates
WO2009141167A1 (en) 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
IT1393136B1 (it) 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6185370A (ja) * 1984-09-24 1986-04-30 ルセル‐ユクラフ ４ｈ‐１，２，４‐トリアゾール誘導体の新製造法、得られる新トリアゾール、それらの薬剤としての使用及びそれらを含む製薬組成物
JPH05222003A (ja) * 1991-06-13 1993-08-31 F Hoffmann La Roche Ag スルホンアミド類および薬物としてのそれらの使用
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
JP2003520857A (ja) * 2000-01-25 2003-07-08 エフ．ホフマン−ラ ロシュ アーゲー スルホンアミドの製造

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 9, JPN6013032141, 2001, pages 2955 - 2968, ISSN: 0002572428 *
CHIMIA, vol. 50, JPN6013032143, 1996, pages 519 - 524, ISSN: 0002572429 *
CHINESE JOURNAL OF MEDICINAL CHEMISTRY, vol. 15, no. 4, JPN6013032145, 2005, pages 230 - 233, ISSN: 0002572430 *
ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 6, no. 2, JPN6013032138, 2002, pages 120 - 124, ISSN: 0002572427 *
PHARM TECH JAPAN, vol. 18, no. 10, JPN7014002019, 2002, pages 81 - 96, ISSN: 0002848776 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508767A (ja) * 2008-01-01 2011-03-17 シプラ・リミテッド ボセンタン、その多形形態及びその塩の合成方法
JP2020143080A (ja) * 2012-04-04 2020-09-10 アルカヘスト インコーポレイテッド Ｃｃｒ３アンタゴニストを含む医薬製剤
US11612596B2 (en) 2012-04-04 2023-03-28 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Also Published As

Publication number Publication date
EP2222649A2 (en) 2010-09-01
AU2008315757A1 (en) 2009-04-30
CN101939303B (zh) 2014-06-11
WO2009053748A3 (en) 2009-06-18
NZ585438A (en) 2012-09-28
US8530488B2 (en) 2013-09-10
NZ600010A (en) 2013-11-29
US20100331352A1 (en) 2010-12-30
CN101939303A (zh) 2011-01-05
WO2009053748A2 (en) 2009-04-30
CA2703230A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
CN101939303B (zh) 波生坦的晶型
AU2008247169B2 (en) Polymorphic forms of bosentan
US20100249162A1 (en) Process for the introduction of hydroxyethoxy side chain in bosentan
US20080161607A1 (en) Processes for preparation of polymorphic form II of sertraline hydrochloride
JP2012507496A (ja) レナリドマイドの結晶形およびその調製方法
KR20040077872A (ko) 카베디롤의 결정질 고체 및 그 제조 방법
JP2007526251A (ja) エゼチミベ多形体
JP2008539278A (ja) 結晶性ロスバスタチンカルシウム
KR20080055990A (ko) 시나칼셋 ＨＣｌ의 결정형 및 이의 제조 방법
JP2013528206A (ja) 結晶形態のサリドマイド及びその調製方法
JP2004526714A (ja) ラモトリジンの新しい結晶形およびそれらの調製方法
JP2004526706A (ja) オクスカルバゼピンの新しい結晶形態及びそれらの調製方法
CN101939301A (zh) 用于制备波生坦的方法
US20060293377A1 (en) Amorphous and polymorphic forms of telmisartan sodium
JP2024539721A (ja) キナーゼ依存性障害の治療のための化合物
EP2610239A1 (en) Preparation Of Rasagiline Hemitartrate
KR101423630B1 (ko) 비칼루타미드와 니코틴아미드의 공결정
US20060052350A1 (en) Crystalline forms of 1,24(S)-dihydroxy vitamin D2
KR20070088507A (ko) 카베딜올의 결정질 형태 및 이것의 제조 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150126